Open AccessS180: RG6234, A NOVEL GPRC5D T‐CELL ENGAGING BISPECIFIC ANTIBODY, INDUCES RAPID RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS FROM A FIRST‐IN‐HUMAN TRIAL
Author(s) -
Hasselbalch Riley C.,
Hutchings M.,
Yoon S.S.,
Koh Y.,
Manier S.,
Facon T.,
Harrison S. J.,
Er J.,
Volzone F.,
Pinto A.,
Montes C.,
Ocio E. M.,
AlfonsoPierola A.,
Rodriguez Otero P.,
Offner F.,
Guidetti A.,
Corradini P.,
Titouan C.,
Hulin C.,
Touzeau C.,
Moreau P.,
Popat R.,
Leong S.,
Mazza R.,
Bröske A.M. E.,
Dekhtiarenko I.,
Helms H.J.,
Belli S.,
Vardar T.,
Fauti T.,
Eckmann J.,
Moore T.,
Schneider M.,
Jacob W.,
Weisser M.,
CarloStella C.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000843612.41180.42
Subject(s) - medicine , refractory (planetary science) , multiple myeloma , adverse effect , cytokine release syndrome , neutropenia , cmax , pharmacodynamics , regimen , clinical trial , pharmacokinetics , oncology , surgery , gastroenterology , toxicity , cancer , immunotherapy , physics , chimeric antigen receptor , astrobiology